


Amendments to the Claims:

1.-20. (Cancelled)



21. (Original) A composition, comprising an agent capable of inhibiting a p75 signal transduction pathway.

22. (Original) A composition according to claim 21, wherein the agent capable of inhibiting the p75 signal transduction pathway is in a form appropriate for delivery to a neuron at a site desired for nerve regeneration.

23. (Original) A composition according to claim 21, wherein the agent capable of inhibiting the p75 signal transduction pathway comprises a transduction agent in the p75 signal transduction pathway or a variant or fragment thereof, or an agent capable of specifically interacting with the transduction agent in the p75 signal transduction pathway.

24. (Withdrawn) A composition according to claim 23, wherein the transduction agent in the p75 signal transduction pathway comprises at least one transduction agent selected from the group consisting of MAG, PKC, IP<sub>3</sub>, GT1b, p75, Rho GDI, Rho, p21, and Rho kinase.

25. (Original) A composition according to claim 21, wherein the agent capable of inhibiting the p75 signal transduction pathway has at least one action selected from the group consisting of inhibition of an interaction between MAG and GT1b, inhibition of PKC, activation of IP<sub>3</sub>, inhibition of an interaction between GT1b and p75, inhibition of an interaction between p75 and Rho, inhibition of an interaction between p75 and Rho GDI, maintenance or enhancement of an interaction between Rho and Rho GDI, inhibition of conversion from Rho GDP to Rho GTP, inhibition of an interaction between Rho and Rho kinase, and inhibition of an activity of Rho kinase.

26. (Original) A composition according to claim 21, wherein the agent capable of inhibiting the p75 signal transduction pathway comprises at least one agent selected from the group consisting of an agent capable of suppressing or extinguishing an interaction between MAG and GT1b, an agent capable of inhibiting PKC, an agent capable of activating IP<sub>3</sub>, an agent capable of suppressing or extinguishing an interaction between GT1b and p75, an agent capable of suppressing or extinguishing an interaction between p75 and Rho GDI, an agent capable of suppressing or extinguishing an interaction between p75 and Rho, an agent capable of maintaining or enhancing an interaction between Rho and Rho GDI, an agent capable of inhibiting conversion from Rho GDP to Rho GTP, an agent capable of inhibiting an interaction between Rho and Rho kinase, and an agent capable of inhibiting an activity of Rho kinase, and wherein the agent capable of inhibiting the p75 signal transduction pathway is present in an amount effective for regeneration.

27. (Original) A composition according to claim 21, wherein the composition is suitable for *in vivo* or *in vitro* administration forms.

28. (Original) A composition according to claim 21, wherein the nerve includes spinal cord injury, cerebrovascular disorder, or brain injury.

29. (Original) A composition according to claim 21, wherein the agent capable of inhibiting the p75 signal transduction pathway comprises at least one molecule selected from the group consisting of a Pep5 polypeptide, a nucleic acid molecule encoding the Pep5 polypeptide, an agent capable of inhibiting PKC, an agent capable of activating IP<sub>3</sub>, an agent capable of specifically interacting with a p75 polypeptide, an agent capable of specifically interacting with a nucleic acid molecule encoding the p75 polypeptide, a p75 extracellular domain polypeptide, a nucleic acid molecule encoding the p75 extracellular domain polypeptide, an agent capable of specifically interacting with a Rho GDI polypeptide, an agent capable of specifically interacting with a nucleic acid molecule encoding the Rho GDI

polypeptide, the Rho GDI polypeptide, a nucleic acid encoding the Rho GDI polypeptide, an agent capable of specifically interacting with a MAG polypeptide, an agent capable of specifically interacting with a nucleic acid molecule encoding the MAG polypeptide, a p21 polypeptide, a nucleic molecule encoding p21, an agent capable of specifically interacting with a Rho polypeptide, an agent capable of specifically interacting with a nucleic acid molecule encoding the Rho polypeptide, an agent capable of specifically interacting with a Rho kinase and an agent capable of specifically interacting with a nucleic acid molecule encoding the Rho kinase, and variants and fragments thereof.

30. (Original) A composition according to claim 21, wherein the agent is bound to a PTD domain.

31.-262. (Cancelled)

If in the opinion of the Examiner a telephone conference would expedite the prosecution of the subject application, the Examiner is encouraged to call the undersigned at (650) 838-4410.

Respectfully submitted,



Jacqueline F. Mahoney  
Registration No. 48,390

**Correspondence Address:**

PAYOR NUMBER 22918  
PHONE: (650) 838-4410  
FAX: (650) 838-4350

Date: August 29, 2005